Early Treatment With Copaxone Benefits MS Patients, Reports New Data

Early Treatment With Copaxone Benefits MS Patients, Reports New Data
Early Treatment With Copaxone Benefits MS Patients, Reports New Data

Teva announced new data on the safety and efficacy of Copaxone (glatiramer acetate injection) 40mg/mL in patients with relapsing forms of multiple sclerosis (MS). The findings were presented at the 67th American Academy of Neurology's (AAN) Annual Meeting in Washington, D.C.

In the 36-month placebo-controlled and open-label extension phases of the Glatiramer Acetate Low-frequency Administration (GALA) study, outcomes of early start (ES) patients (n=834) who received three-times-a-week Copaxone 40mg/mL for 36 months were compared to delayed start (DS) patients (n=419) who initiated Copaxone after the 12-month placebo-controlled phase of the trial. The adjusted mean annualized relapse rate was significantly lower for the ES patients over 36 months (0.23 vs. 0.30, risk ratio [RR]=0.770; P=0.0052) and early treatment was associated with a sustained reduction in lesion activity and the evolution of active lesions to chronic black holes.

RELATED: FDA Approves New Copaxone 40mg Strength

Copaxone is indicated to reduce the frequency of relapses in patients with relapsing-remitting MS, including those who have experienced a first clinical episode and have MRI features consistent with MS.

For more information call (800) 221-4026 or visit TevaUSA.com.